

An Economic Assessment of the Cost of Cancer in Texas
and the Benefits of the
Cancer Prevention and Research Institute of Texas (CPRIT)
and its Programs:

2023 Update

THE PERRYMAN GROUP

510 N. Valley Mills Dr., Suite 300

Waco, TX 76710

ph. 254.751.9595, fax 254.751.7855

info@perrymangroup.com

www.perrymangroup.com



Contents

Summary of Key Results.....	1
Introduction	3
The Economic Cost of Cancer in Texas.....	6
Cancer Incidence	6
Cancer Costs	7
Total Economic Cost of Cancer	12
Cost of Top Death Causing Cancers.....	15
Estimate of Impact of Delayed Cancer Screening and Treatment Arising from COVID-19 Pandemic	16
Benefits of Screening and Prevention	17
The Economic Impact of CPRIT and its Programs	18
Benefits of CPRIT Operations and Spending.....	18
Secondary Benefits.....	19
Overall Total Current Impact of CPRIT Operations (including Secondary Effects)	20
Further CPRIT Benefits	22
A Broader Perspective.....	24
Conclusion.....	26

Summary of Key Results

- The direct **cost of cancer** in Texas, as traditionally measured, is estimated to be almost **\$56.3 billion** in 2023 (compared to about \$51.0 billion in 2022), with total economic **losses** (including multiplier effects) of an estimated **\$147.9 billion** in output and **1,252,870** jobs.
- The current total annual impact of all CPRIT operations, prevention/screening, and research programs (including initial outlays and multiplier effects) includes **\$630.8 million** in output (real gross product) in 2023 as well as **7,377** jobs. When all secondary and downstream benefits are considered, these values rise to almost **\$23.8 billion** in output and **201,911** jobs.
- This incremental business activity generates **taxes for the State and local governments**.
 - In 2023, annual tax receipts associated with CPRIT grants and programs (including downstream effects) total more than **\$1.3 billion** to Texas, a notable increase over last year's almost **\$1.2 billion**; local public entities receive **\$560.1 million**.
 - Since the inception of CPRIT, these gross incremental taxes total just over **\$19.5 billion** for the State and almost **\$8.4 billion** for local governments.
 - The net incremental taxes (which nets out the potential benefits of other typical uses of State funds over the period since inception) include **\$19.0 billion** to the State and **\$8.1 billion** to local governments.
 - These amounts are well in excess of the total commitment of State resources. Notable gains in benefits in recent years reflect factors such as the compounding effects over time and the substantial matching funds that are being leveraged by CPRIT activities.

Every Dollar Invested Through CPRIT Returns: (Including Initial Outlays and Secondary (Downstream) Effects)	
\$27.82	In Treatment Cost Savings and Resulting Economic Benefits through Earlier Detection from Prevention/Screening Activity in 2023
\$204.64	In Economic Activity (Total Expenditures) in 2023
\$99.56	In Output (Real Gross Product) in 2023
\$59.94	In Personal Income in 2023
\$28.08	In Retail Sales in 2023
\$4.89	In State Tax Receipts as of 2023
\$2.08	In Local Government Tax Receipts as of 2023

Source: The Perryman Group

- It is worthy of note that, since 2010, Texas has seen growth in bioscience manufacturing employment of about 35.2%. The pace is far in excess of that of the United States (16.5%) and states that have traditionally been major centers of such activity. Expansion in competing states is far lower, including California (14.5%), North Carolina (14.4%), Illinois (13.8%), Georgia (10.6%), Massachusetts (5.9%), Ohio (4.7%), and Pennsylvania (-2.8%). While there are other factors that support the success in Texas, the investments and programs supported by CPRIT are the major differentiating factor. This performance and the success of CPRIT were significant factors in the selection of Texas as a major hub for the new Advanced Research Projects Agency for Health (ARPA-H) initiative.
- **Basic medical research is also a part of society's essential infrastructure, and CPRIT has demonstrated the capacity to enhance the health of Texans and the economy at a pace that far exceeds the direct investment.**
- These results are explained more fully in subsequent sections and the Appendices of this report.

Introduction

The Cancer Prevention and Research Institute of Texas (CPRIT) has been working to reduce the tragically high human and financial cost of cancer since 2010.

CPRIT has helped attract more than 295 leading cancer research scientists and their labs to Texas from both US and international locations (including members of the prestigious National Academy of Sciences) as well as recruit 17 companies.

CPRIT scholar Dr. James Allison, who was recruited to MD Anderson Cancer

Center as part of a \$10 million CPRIT grant in 2011, was awarded the 2018 Nobel Prize in physiology or medicine, along with Tasaku Honjo, for his work in cancer immunotherapy. In September 2020, multiple CPRIT award recipient Dr. Zhijian "James"

Reducing the burden of cancer provides benefits to individuals, families, hospitals, state and local governments, insurance providers, and society as a whole.

Chen received the 2020 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the Cancer Research Institute. Many other CPRIT scholars have received prestigious awards as well.

CPRIT reports that funded projects have resulted in over 1,116 published articles in fiscal 2023, and 39 patent filings and 5 patents granted in fiscal 2023. CPRIT funding has led to 273 clinical trials or studies with over 48,800 patients enrolled. In addition, CPRIT grants for screening and related education have provided 9.04 million prevention services (education and training services and clinical services) to Texans from all 254 counties and are improving access to lifesaving testing for some of the state's most vulnerable populations.

In addition to their positive effect on health and wellbeing, CPRIT activities generate sizable economic benefits.

Reducing the burden of cancer provides benefits to individuals, families, hospitals, state and local governments, insurance providers, and society as a whole. Through research and prevention/screening, cancer incidence and severity can be notably reduced, providing relief in terms of health outcomes and quality of life, as well as notable benefits to the economy. Medical outlays can be decreased through

earlier detection, and improving results benefit both patients and society as a whole through enhancing the productivity and lifespan of those affected by cancer. In addition, research activity, apart from its primary mission to drive fundamental breakthroughs, can serve as a catalyst for business development in related industries (such as biomedicine).

In addition to their positive effect on health and wellbeing, CPRIT activities generate sizable economic benefits. The Perryman Group (TPG) has quantified the cost of cancer in Texas and the economic benefits of CPRIT for several years. This report updates the findings from TPG's analysis utilizing the most recent data regarding cancer incidence and results to date from CPRIT grants, following the same general methodology and report structure to aid in comparisons of results across years.

Report Components

An approach consistent to prior years was used where possible in this 2023 update. At present, the initial CPRIT grants have been in place for about 14 years. Recipients have reported progress, hiring, matching funds, and other key performance metrics. Firms have also located to Texas or expanded as a result of CPRIT efforts. This information was used in assessing the economic impacts related to research to the extent possible and, as in last year's update, were used to validate model results. The major components of The Perryman Group's analysis include the following:

The **economic cost of cancer** in terms of Texas business activity including losses stemming from treatment, morbidity, and mortality as well as the associated spillover effects are initially estimated. Data regarding the numbers of Texans with cancer and the associated costs for direct medical expenses, morbidity costs, and mortality are the subject of reports by entities such as the National Institutes of Health, the American Cancer Society, the National Cancer Institute (Centers for Disease Control (CDC)), and the Texas Cancer Registry (Texas Department of State Health Services). The projected costs of cancer treatment in 2023 and 2033 and an estimated breakout of cancer expenditures by payer in 2022 are also given. An analysis of the losses associated with the top four cancer sites for annual deaths in Texas for 2023 (lung and bronchus, colorectal, breast, and pancreas) are also provided. Additionally, an estimate of the impact of delayed cancer screening and treatment due to the COVID-19 pandemic is provided.

The **overall effect of CPRIT operations** on business activity in Texas (including multiplier effects) is estimated using input data regarding direct expenditures and operations employment at the Institute.

The **positive economic benefits of CPRIT-supported cancer prevention and screening programs** are also assessed, including both the increase in business activity due to the screenings themselves and the associated benefits from improved health. The effects of matching funds generated by CPRIT programs were also included.

Economic returns on research supported by the Institute (including the effects related to the specific outlays, actual and anticipated recruitment efforts for high quality scholars in relevant areas, typical returns on medical research investments, and spinoff companies that surface from such endeavors) were also evaluated. Again, associated matching funds are incorporated into the analysis.

Some illustrative scenarios related to **potential economic development and social gains** (a recently added feature) stemming from the Institute's role as a catalyst for incremental business activity are provided, as well as others demonstrating the economic value of increased quality of life, longevity, and productivity from improved outcomes.

The Appendices provide a detailed discussion of all technical aspects of the report, including methodology and disaggregated results.

The Economic Cost of Cancer in Texas

Cancer affects the longevity, quality of life, and finances of individuals suffering with the illness. Costs associated with cancer include direct medical outlays for treatment and care as well as indirect costs such as disease-related work disability or premature mortality. Prevention, early detection, effective treatment, and medical advances to minimize the consequences of the disease are vital national and, indeed, global priorities.

Despite advances in many aspects of cancer prevention and treatment, the number of Americans diagnosed with the disease remains very high. One factor in the recent upward trend in new cases is the aging of the US population, as cancer incidence increases among older age groups. The COVID-19 pandemic during 2020 that continued into 2022 and the resulting shutdowns led to many appointments being missed, cancelled, or delayed and will likely lead to increased cancer cases, severity, and deaths over time. TPG has calculated a preliminary estimate of the economic impact of delayed cancer screening and treatment discussed later in the report.

Cancer Incidence

The American Cancer Society estimates that there will be about 1,958,310 new cases of cancer (1,010,310 male and 948,000 female) and 609,820 deaths from cancer (322,080 male and 287,740 female) in the US in 2023. The number of new cases expected in 2023 is about 40,280 higher than the projected number for 2022 as cases for both males and females are expected to increase. The estimated cancer deaths show a slight increase overall with male deaths about the same and female deaths slightly higher compared to 2022.¹

In Texas, a total of 139,100 new cases of cancer are anticipated in 2023, with 44,140 cancer deaths projected according to the American Cancer Society.²

¹ American Cancer Society, *Cancer Facts & Figures 2023*, Atlanta, American Cancer Society, 2023. Note these estimates are based on reported cancer incidence and mortality through 2019 and 2020, respectively, and projected cancer cases in 2023 do not account for the impact of the coronavirus disease 2019 (COVID-19) pandemic on cancer diagnoses, and the projected cancer deaths in 2023 only account for the first year.

² American Cancer Society, *Cancer Facts & Figures 2023*, Atlanta, American Cancer Society, 2023.

Compared to the estimates for 2022, approximately 220 fewer cases and about 650 more deaths are expected in 2023. The Texas Cancer Registry projects slightly different numbers for Texas in 2023 than the American Cancer Society with 140,436 new cases (72,787 male and 67,648 female), as well as 47,887 deaths (25,873 male and 22,014 female).³ Cancer remains the second most common cause of death after heart disease.⁴

Cancer Costs

Apart from the extremely high human cost, cancer causes economic harms to affected individuals, businesses, and society as a whole through shortened life spans, lost productivity, increased health care expenditures, and premature mortality.

The direct medical costs and morbidity and mortality losses (as traditionally measured) in the state totaled an estimated \$56.3 billion in 2023, up from \$51.0

The direct medical costs of cancer and morbidity and mortality losses (as traditionally measured) in the state totaled an estimated \$56.3 billion in 2023, increasing over the past few years.

billion in 2022 and \$47.7 billion two years ago (according to TPG's update of existing information from the National Institutes of Health⁵ and a study of costs in Texas)⁶ as well as other data from several more recent studies.⁷ In 2010, cancer

³ "Expected New Cancer Cases and Deaths by Primary Site, Texas, 2023," Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services, March 2023. Because of the additional detail provided in these estimates, they are used in much of the current analysis.

⁴ American Cancer Society, *Cancer Facts & Figures 2023*, Atlanta, American Cancer Society, 2023.

⁵ The National Institutes of Health (NIH) estimated the total overall cost of cancer in 2010 (the latest year for which such information is available) to be \$263.8 billion including direct medical costs of \$102.8 billion (including the total of all health expenditures), indirect morbidity costs (the cost of lost productivity due to illness) of \$20.9 billion, and indirect mortality costs (the cost of lost productivity due to premature death) of \$140.1 billion. See *Cancer Facts & Figures 2011*, American Cancer Society, 2011.

⁶ A study directed by the Texas Department of State Health Services (DSHS) and conducted by scholars at the University of Texas Medical Branch (UTMB) found that the total cost of cancer in the state was roughly \$21.9 billion in 2007, with \$10.0 billion in direct medical costs and \$11.8 billion in indirect costs from lost productivity due to cancer morbidity and mortality. See Philips, B.U., et al., *The Cost of Cancer in Texas 2007*, Department of Preventive Medicine and Community Health; Texas Medical Branch at Galveston, March 2009.

⁷ Data from several other studies were used to refine the cost of cancer estimate. See Yabroff, K. Robin, et al., *Annual Report to the Nation on Status of Cancer, Part 2: Patient Economic Burden Associated with Cancer*, Journal of the National Cancer

treatment costs in Texas were about \$11.5 billion in current dollars and \$16.1 billion in constant 2023 dollars. In 2023, treatment costs are estimated to be about \$23.1 billion in current and constant 2023 dollars (a 101.3% and 43.3% rise, respectively). By 2033, the projected costs are expected to be \$34.2 billion in current dollars, 48.3% higher than in 2023. In constant 2023 dollars, the costs are projected to be almost \$27.3 billion by 2033, an 18.4% increase over 2023. The projected rates of increase at the national level are even higher.

Costs of cancer treatment are covered by private insurance companies, social programs such as Medicare and Medicaid, and by the patients themselves.

- The Perryman Group estimates that the cost of cancer treatment to private insurance companies in Texas in 2022 was almost \$8.6 billion.
- The cost of treating cancer in Texas paid through Medicaid in 2022 was \$488.7 million.
- The CHIP program spent almost \$4.1 million treating cancer in 2022.
- Costs of cancer treatment to Medicare in Texas in 2022 totaled an estimated \$5.9 billion.
- The cost of cancer treatment to the Teacher Retirement System of Texas for 2022 was about \$791.9 million while the cost to the Employment Retirement System of Texas was about \$438.0 million.⁸
- The cost of treating cancer to other third-party payers in 2022 was determined to be almost \$4.0 billion.
- The out-of-pocket cost to cancer patients in Texas in 2022 was approximately \$2.9 billion.⁹


Institute, October 26, 2021,

<https://academic.oup.com/jnci/article/113/12/1670/6409890><https://academic.oup.com/jnci/article/113/12/1670/6409890>; Park, Joohyun, and Kevin Look, Health Care Expenditure Burden of Cancer Care in the United States, National Library of Medicine, October 4, 2019, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778988/>; Mariotto, Angela B. et al., Medical Care Costs Associated with Cancer Survivorship in the United States, *Cancer Epidemiol Biomarkers Prev.*, July 2020, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514601/>; and Financial Burden of Cancer, National Cancer Institute, *Cancer Trends Progress Report*, August 2023, https://progressreport.cancer.gov/after/economic_burden.

⁸ Data provided by TRS and ERS personnel.

⁹ Medicaid and CHIP cancer expenditure data from AHQP Claims Universe, Texas Medicaid and Healthcare Partnership (TMHP); Enc_Best Picture Universe, TMHP; prepared by Data Dissemination and Reporting, Office of Data, Analytics, and Performance, Texas Health and Human Services Commission (HHSC), November 2023. All other expenditures are approximations by The Perryman Group based on best available data.

Cancer Treatment Costs Allocation by Payer in Texas 2022



Sources: Medicaid and CHIP cancer expenditure data from AHQP Claims Universe, Texas Medicaid and Healthcare Partnership (TMHP); Enc_Best Picture Universe, TMHP; prepared by Data Dissemination and Reporting, Office of Data, Analytics, and Performance, HHSC, November 2023. All other expenditures are approximations by The Perryman Group based on best available data.

The cost of cancer goes well beyond initial effects. Several studies have clearly portrayed the very large economic losses associated with cancer. While many of these are excellent analyses, they fail to capture numerous “multiplier” effects associated with the disease and, thus, represent only a portion of the overall toll on business activity (only the initial effect of the various categories of cost).

Most studies of cancer costs reflect only the initial effect of direct medical outlays for treatment and care and indirect costs such as disease-related work disability or premature mortality are not included. However, these losses, in turn, generate further reductions in business activity.

The cost of cancer goes well beyond initial impacts. It also includes associated foregone spillover effects.

Several years ago, The Perryman Group developed a more comprehensive measure of the cost of cancer which includes losses stemming from treatment, morbidity, and mortality as well as the associated foregone spillover effects. This more comprehensive measure is quantified in the approach utilized by The Perryman Group in the current analysis.

Measuring Economic Impacts

Any economic stimulus, whether positive (such as direct spending, investments, or corporate activity) or negative (such as lost productivity due to disease) generates multiplier effects throughout the economy. In this instance, economic costs of cancer include not only the initial incidence of costs, but also the subsequent rounds of economic activity which are forgone. Economic benefits of cancer research and prevention/screening activities include, among others, increased research spending, commercialization of discoveries, enhanced screening programs, and higher productivity stemming from better health outcomes. (These channels of benefits are described within the report and the accompanying Appendices.) Once the direct stimulus was quantified, the associated multiplier effects were measured.

The Perryman Group's dynamic input-output assessment model (the US Multi-Regional Impact Assessment System, which is described in further detail in the Appendices to this report) was developed by The Perryman Group about 40 years ago and has been consistently maintained and updated since that time; it has been used in hundreds of analyses for clients ranging from major corporations to government agencies. The system uses a variety of data (from surveys, industry information, and other sources) to describe the various goods and services (known as resources or inputs) required to produce another good/service. This process allows for estimation of the total economic impact (including multiplier effects) of CPRIT programs and related activity. An associated fiscal model allows for estimation of tax receipts to state and local entities. The submodels used in the current analysis reflect the specific industrial composition and characteristics of the Texas economy and its various counties, metropolitan areas, regions, and legislative districts.

These total economic effects are quantified for key measures of business activity:

- **Total expenditures** (or total spending) measure the dollars changing hands as a result of the economic stimulus.
- **Gross product** (or output) is production of goods and services that will come about in each area as a result of the activity. This measure is parallel to the gross domestic product numbers commonly reported by various media outlets and is a subset of total expenditures.
- **Personal income** is dollars that end up in the hands of people in the area; the vast majority of this aggregate derives from the earnings of employees, but payments such as interest and rents are also included.
- **Job gains** are expressed as (1) job-years of employment (equivalent to one person working for one year but it could be multiple people working part of a year) for temporary projects (such as construction of a facility) or cumulative assessments over time or (2) jobs when evaluating ongoing annual effects.

Dynamic State and local government revenues reflect tax receipts stemming from the increase in total economic activity. Monetary values were quantified on a constant (2023) basis, which eliminates inflationary effects and allows comparison across various time periods. See the Appendices to this report for more detailed information regarding the methods and assumptions used in this analysis.

Total Economic Cost of Cancer

Using The Perryman Group's more comprehensive measure, the total cost of cancer to the Texas economy is estimated to be about **\$300.1 billion** in reduced annual spending,

Using The Perryman Group's more comprehensive measure, the total cost of cancer to the Texas economy is estimated to be more than \$147.9 billion in output losses per annum and more than 1.2 million lost jobs.

\$147.9 billion in output losses per annum, and approximately **1,252,870** lost jobs from cancer treatment, morbidity, and mortality and the associated spillover effects. These amounts represent a slight increase over last year's

estimated total cost of \$280.8 billion in spending, \$138.4 billion in output, and 1,248,240 jobs. **These totals represent approximately 5.68% of the total output of the Texas economy, 6.20% of earnings, and 8.67% of employment.**

The yearly loss in State fiscal revenues (including Medicaid and CHIP and uncompensated care) is almost **\$9.3 billion**, while losses to local governments include about **\$5.0 billion** per annum.

The yearly loss in State fiscal revenues (including Medicaid and CHIP and uncompensated care) is almost \$9.3 billion, while losses to local governments include about \$5.0 billion per annum.

Losses are spread across all regions of Texas and are concentrated in the state's most populous areas. Details of these losses from cancer treatment, morbidity, and mortality and the associated spillover effects are shown in the following table.

The Total Annual Impact of Losses (Treatment, Morbidity, and Mortality) Associated with the Incidence of Cancer on Business Activity in Texas				
(Monetary Values in Billions of Constant 2023 Dollars)				
	Treatment	Morbidity	Mortality	TOTAL
Total Expenditures	(\$76.0)	(\$64.5)	(\$159.6)	(\$300.1)
Gross Product	(\$38.2)	(\$31.6)	(\$78.1)	(\$147.9)
Personal Income	(\$25.2)	(\$18.3)	(\$45.2)	(\$88.7)
Retail Sales	(\$9.8)	(\$9.4)	(\$23.2)	(\$42.4)
Employment (Jobs)	(357,592)	(251,216)	(644,064)	(1,252,871)

Note: Totals may not equal sum of components due to independent rounding.
Source: The Perryman Group

COST OF CANCER BY COUNCIL OF GOVERNMENTS REGION

ECONOMIC COST OF CANCER INCLUDING DIRECT MEDICAL EXPENSES AND PREMATURE
MORBIDITY AND MORTALITY



ANNUAL EFFECT ON BUSINESS ACTIVITY		
	GROSS PRODUCT (Billions of 2023 Dollars)	EMPLOYMENT (Jobs)
Panhandle	(\$2.7)	(23,328)
South Plains	(\$2.5)	(22,664)
Nortex	(\$2.0)	(17,268)
North Central Texas	(\$36.3)	(300,012)
Ark-Tex	(\$2.2)	(20,581)
East Texas	(\$7.3)	(63,290)
West Central Texas	(\$2.8)	(24,527)
Rio Grande	(\$4.6)	(40,407)
Permian Basin	(\$2.6)	(21,163)
Concho Valley	(\$1.2)	(10,184)
Heart of Texas	(\$2.8)	(25,732)
Capital Area	(\$7.6)	(67,851)
Brazos Valley	(\$1.7)	(15,370)
Deep East Texas	(\$3.2)	(29,861)
South East Texas	(\$3.2)	(29,124)
Houston-Galveston Area	(\$35.1)	(270,033)
Golden Crescent	(\$1.5)	(12,808)
Alamo Area	(\$14.0)	(124,716)
South Texas	(\$1.1)	(9,563)
Coastal Bend	(\$4.1)	(34,970)
Lower Rio Grande Valley	(\$4.6)	(43,361)
Texoma	(\$1.6)	(15,223)
Central Texas	(\$2.4)	(22,833)
Middle Rio Grande	(\$0.8)	(8,000)
Border Region	(\$11.1)	(101,374)
TOTAL STATE	(\$147.9)	(1,252,871)

Note: Border Region includes Rio Grande, Terrell County, Middle Rio Grande, South Texas, and Lower Rio Grande Valley

Source: The Perryman Group

Cost of Top Death Causing Cancers

The Perryman Group also analyzed the losses associated with the top four cancer sites for annual deaths in Texas, which include lung and bronchus, colorectal, breast, and pancreas.

The Perryman Group determined the total direct annual medical cost of these cancers in Texas for 2023 is about

\$4.4 billion. The analysis also indicates a total cost to the Texas economy of almost **\$55.9 billion** in reduced annual spending, **\$27.5 billion** in reduced output per year, and **233,900** lost jobs from cancer treatment, morbidity, and mortality and the associated spillover effects.

The top four cancer sites for annual deaths in Texas cost the state economy \$27.5 billion in reduced output per year and 233,900 lost jobs.

The following table illustrates total lifetime losses associated with the deaths in 2023 and other effects resulting from these four sites.

The Total Impact of Losses (Treatment, Morbidity, and Mortality) Associated with Lung and Bronchus, Colorectal, Breast, and Pancreatic Cancer Deaths in 2023 and Other Effects on Texas Business Activity

(Monetary Values in Billions of Constant 2023 Dollars)

	Lung and Bronchus	Colorectal	Breast	Pancreatic	TOTAL
Total Expenditures	(\$27.7)	(\$12.4)	(\$6.8)	(\$8.9)	(\$55.9)
Gross Product	(\$13.7)	(\$6.1)	(\$3.3)	(\$4.4)	(\$27.5)
Personal Income	(\$8.2)	(\$3.7)	(\$2.0)	(\$2.6)	(\$16.5)
Retail Sales	(\$3.9)	(\$1.8)	(\$1.0)	(\$1.3)	(\$7.9)
Employment (Jobs)	(116,365)	(51,817)	(28,351)	(37,373)	(233,906)

Note: Medical costs based on (1) estimated costs per site for cancer cases over the diagnosis period as estimated by the National Institutes of Health (adjusted to reflect current dollars based on the Medical Services CPI for Texas areas as maintained by the US Bureau of Labor Statistics), (2) estimated incidence and deaths by cancer site in Texas for 2023 as compiled by the Texas Cancer Registry, and (3) estimated patterns following diagnosis based on patterns of incidence and death by site. Morbidity and mortality effects are estimated based on patterns relative to medical costs in Texas and approximate cost allocations over the disease cycle (which provides a reasonable proxy for morbidity and mortality patterns). Totals may not equal sum of components due to independent rounding.

Source: The Perryman Group

Details of losses from treatment, morbidity, and mortality for each of these cancers can be found in the Appendices.

Estimate of Impact of Delayed Cancer Screening and Treatment Arising from COVID-19 Pandemic

As mentioned previously, the COVID-19 pandemic which began in 2020 and continued into 2022 and the resulting shutdowns led to many appointments being missed, cancelled, or delayed and will likely lead to increased cancer cases, severity, and deaths over time. TPG used available information to provide a preliminary estimate of the impact of delays in cancer screening and treatment due to the COVID-19 pandemic and related disruptions. TPG estimates the delayed cancer screening and treatment associated with the COVID-19 pandemic will lead to decreased annual output in Texas of almost **\$15.8 billion** and **128,920** lost job years of employment over the life of those not tested and treated.

These results will be refined in future years as additional information becomes available. This scenario is derived from an assessment of consensus estimates from numerous studies based on mortality and incidence expectations in a limited number of sites, with appropriate adjustments for other sites and morbidity effects using current patterns.¹⁰ The estimates do not include medical costs, as there is insufficient data to determine the net effects of longer care relative to greater severity.

¹⁰ See for example, Lum, Sharon, et al., Disruption of National Cancer Database Data Models in the First Year of the COVID-19 Pandemic, *JAMA Surgery*, April 12, 2023, <https://jamanetwork.com/journals/jamasurgery/fullarticle/2802991>; Negoita, Serban, et al., Annual Report to the Nation on the Status of Cancer. Part 2: Early Assessment of the COVID-19 Pandemic's Impact on Cancer Diagnosis, *Cancer*, August 11, 2023, <https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35026>; and Romatoski, Kelsey, et al., Delay and Disparity in Observed vs Predicted Incidence Rate of Screenable Cancer During the COVID-19 Pandemic, *American College of Surgeons*, Vol. 237, No. 3, September 2023, https://journals.lww.com/journalacs/abstract/2023/09000/delay_and_disparity_in_observed_vs_predicted.5.aspx.

Benefits of Screening and Prevention

It is far less expensive to screen for cancer and treat it in its early stages. Not only

Every \$1 spent through CPRIT for screening/prevention saves \$2.05 in direct health spending and leads to a total of \$27.82 in treatment cost savings and resulting economic benefits through earlier detection.

to \$27.82 in treatment cost savings and resulting economic benefits through earlier detection.¹¹ The Perryman Group's analysis also estimates that every \$1 spent on screening/prevention saves \$2.05 in direct health spending (these savings are included in the \$27.82 listed above).

¹¹ The reported benefits from screening and prevention are significantly higher than in some earlier years based on recent and more comprehensive research which illustrates greater rates of return on prevention and screening than prior evidence. See, for example, Boland, Mairin and Joan Murphy, The Economic Argument for Prevention of Ill-health at Population Level, For Working Group on Public Health Policy Framework, May 2012.

The Economic Impact of CPRIT and its Programs

The overall effects of CPRIT and its various initiatives extend well beyond the initial stimulus and impacts business activity throughout the supply chain. Even beyond the potentially life-changing influence of spending to reduce the incidence and severity of the disease, this investment in research, screening, and related activities generates substantial economic impacts. Moreover, the investment has the potential to reduce the cost of cancer through improving outcomes.

Returns on investments in medical research include jobs created in the private sector, health care costs saved, the value of increased longevity, the value of

The direct outlays and related “multiplier” effects emanating from CPRIT operations and programs generate a sizable increase in business activity in Texas including \$630.8 million in output (gross product) and 7,377 jobs.

reduced morbidity and disability, and the benefits of newer medicines and therapies. Job creation occurs not only directly through the scientists and staff in the research facilities, but also indirectly through the provision of business services needed by those institutions and other multiplier effects.

Many studies over an extended period of time support the conclusion that investing in medical and cancer research can yield returns far in excess of initial outlays. Texas is already seeing tangible job gains and other benefits such as attracting top-tier research talent (including the CPRIT scholar, Dr. James Allison, who was awarded the 2018 Nobel Prize in physiology or medicine, along with Tasuku Honjo, for his work in cancer immunotherapy), external research funding, and commercialization of findings.

Benefits of CPRIT Operations and Spending

The direct outlays and related “multiplier” effects emanating from CPRIT operations and programs generate a sizable increase in business activity in Texas

including **\$630.8 million** in output (gross product) and **7,377** jobs during fiscal year 2023.

These economic benefits stem from operations, prevention and screening, and research programs. They are consistent with the results reported by grant recipients and other data available regarding CPRIT initiatives. Fiscal benefits are also significant, as noted in the table below.

The Current Impact of CPRIT Direct Operations, Prevention and Screening, and Research Programs on Texas Business Activity and Tax Receipts (Monetary Values in Millions of Constant 2023 Dollars)				
ECONOMIC BENEFITS				
	Operations	Prevention & Screening	Research	TOTAL
Total Expenditures	\$38.0	\$116.4	\$1,055.8	\$1,210.1
Gross Product	\$19.3	\$63.4	\$548.2	\$630.8
Personal Income	\$13.2	\$44.3	\$379.8	\$437.3
Retail Sales	\$5.0	\$16.6	\$144.4	\$166.0
Employment (Jobs)	143	659	6,574	7,377
FISCAL BENEFITS				
State (Texas)	\$1.0	\$3.1	\$28.0	\$32.1
Local Governmental Entities Throughout the State	\$0.4	\$1.6	\$15.3	\$17.3
Note: Totals may not equal sum of components due to independent rounding. Source: The Perryman Group				

Secondary Benefits

Even beyond these substantial gains in business activity, CPRIT programs lead to secondary (downstream) benefits such as improved outcomes stemming from screening and prevention and research. Screening can help reduce cancer incidence and severity. TPG estimates the total annual net outcomes-related

benefits from screening and prevention supported by CPRIT to be **\$379.4 million** in output (gross product) and **3,214** jobs in 2023 including multiplier effects (on a net present value basis assuming typical outcomes from available academic studies). Effects since the inception of CPRIT programs are included in the Appendices to this report.

The economic benefits of CPRIT-funded research activity compound over time. Current estimates of these secondary effects stemming from research include almost **\$22.8 billion** in output and **191,320** jobs in 2023 (including multiplier effects). These gains are expected to grow substantially in future years as programs continue and benefits cumulate (as indicated in the Appendices).

The cancer research supported by CPRIT also generates substantial social returns. The estimated cumulative social returns from the cancer research supported by CPRIT from 2010-2023 include almost **\$700.8 billion** in gross product in the United States and **\$862.0 billion** globally. The impact on employment in the US is **5,782,152** job-years of employment and globally is **7,112,047** job years.¹²

Overall Total Current Impact of CPRIT Operations (including Secondary Effects)

Adding the economic benefits of CPRIT operations, prevention/screening programs, research, outcomes-based prevention/screening, and secondary research effects yield a total gross impact of the Institute's operations. The current annual total gross impact of CPRIT on Texas business activity (including multiplier effects) was found to include almost **\$23.8 billion** in output, and **201,911** jobs in 2023. Fiscal benefits are also substantial, as noted in the following table.

¹² Social returns have been included in the last few years based on recent academic research. See, in particular, Hall, Bronwyn, Jacques Mairesse, and Pierre Mohnen; Measuring the Returns to R&D; chapter prepared for the Handbook of the Economics of Innovation, editors B.H. Hall and N. Rosenberg, December 2009; Frontier Economics, Rates of Return to Investment in Science and Innovation, report prepared for the Department for Business Innovation and Skills, July 2014.

Because of the cumulative nature of research gains, these benefits increase over time. Even when other potential uses for State funding of CPRIT are considered,

the net economic benefits remain substantial (as indicated in the Appendices). Over an extended time horizon, CPRIT and the research funding it provides will likely generate fiscal receipts

The total economic benefits of CPRIT operations, prevention/screening programs, research, outcomes-based prevention/screening, and secondary research effects was found to include almost \$23.8 billion in output each year, and 201,911 jobs (including multiplier effects).

totaling a multiple of the commitment of public resources (in addition to the notable economic and health benefits).

The Overall Total Gross Annual Impact of CPRIT Operations, Prevention/Screening, and Research Programs on Texas Business Activity and Tax Receipts (Including Direct Outlays with Multiplier Effects as Well as Secondary Effects)
(Monetary Values in Millions of Constant 2023 Dollars)

ECONOMIC BENEFITS*

Total Expenditures	\$48,897.4
Gross Product	\$23,775.7
Personal Income	\$14,381.2
Retail Sales	\$6,673.3
Employment (Jobs)	201,911

FISCAL BENEFITS

State (Texas)	\$1,310.5
Local Governmental Entities Throughout the State	\$560.1

*Based on budgeted operations and reported awards in fiscal year 2023.
Source: The Perryman Group

Further CPRIT Benefits

The ultimate goal of CPRIT is reducing cancer incidence and the associated high human and economic costs, and a major reduction in incidence/severity would yield substantial economic benefits. In addition, the research activity supported by CPRIT can serve as a catalyst for economic development.

If CPRIT's screening/prevention programs, research advances, and other initiatives **reduce the incidence of cancer in Texas over time to equal the average of current levels observed in the five states with the lowest incidence and death rates, notable economic benefits would be realized.** The Perryman Group estimates that the gains in Texas stemming from a **substantial reduction in cancer incidence by 2053 would include almost \$24.0 billion in gross product and about 202,990 permanent jobs.**

Fiscal benefits of such a reduction in cancer incidence include an estimated \$1.3 billion to the State each year and \$573.6 million to local government entities (in constant 2023 dollars). Moreover, these benefits do not include the obvious gains in quality of life and

If CPRIT's screening/prevention programs, research advances, and other initiatives reduce the incidence of cancer over time to equal the average of current levels observed in the five states with the lowest incidence and death rates, gains in Texas by 2053 would include almost \$24.0 billion in gross product and about 202,990 permanent jobs as well as an estimated \$1.3 billion to the State each year and \$573.6 million to local government entities (in constant 2023 dollars).

Research activity associated with CPRIT is enhancing Texas' position in a number of related industries.

Research activity associated with CPRIT is enhancing Texas' position in a number of related industries. Since 2010, CPRIT has funded 1,901 awards for cancer research, product development, and prevention with the awards totaling

would not be restricted to Texas; they would bring better outcomes throughout the country and, indeed, the entire world.

\$3,380,673,266.¹³ CPRIT has enjoyed a number of successes, and its programs and grants are helping attract key researchers and companies to Texas. As mentioned previously, CPRIT scholars have received numerous prestigious awards including the 2018 Nobel Prize in physiology or medicine awarded to Dr. James Allison, (along with Tasuku Honjo) for his work in cancer immunotherapy. In September 2020, multiple CPRIT award recipient Dr. Zhijian "James" Chen received the 2020 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the Cancer Research Institute. CPRIT's investments have played a critical role in connecting universities, researchers, private companies, hospitals, clinics, and physicians across Texas in the battle against cancer. CPRIT has recruited 295 cancer researchers and their labs to Texas. CPRIT's efforts have resulted in 273 new clinical studies with more than 48,800 patients enrolled through CPRIT programs. CPRIT has delivered 9.04 million prevention services to Texans from every county in the state. CPRIT-funded academic grantees and companies have raised \$9.486 billion in non-state follow-on funding above contract awards. In addition to helping save lives, these grants have the potential to generate significant returns to CPRIT as well. CPRIT has funded research projects which have resulted in over 1,116 publications and 39 patents filed and 5 granted in the 2023 fiscal year.¹⁴

The Institute's role as a potential catalyst for development of Texas' biomedical industries is helping to establish the Lone Star State as a center for such

If Texas achieves a concentration in the biomedical industry (pharmaceuticals and medical equipment) by 2053 equivalent to that of the US, incremental gains would include almost \$47.2 billion in annual gross product and 264,728 jobs.

equation) by 2053 equivalent to that of the US, incremental gains would include almost \$47.2 billion in annual gross product and 264,728 jobs. If the state's concentration in the biomedical industry in 2053 reached a level equivalent to

development. The economic gains from this type of economic development have been and will continue to be significant. The Perryman Group estimates that if Texas achieves a concentration in the biomedical industry (pharmaceuticals and medical

¹³ Grants Funded, Cancer Prevention & Research Institute of Texas website, <https://www.cprit.state.tx.us/grants-funded>, accessed November 14, 2023.

¹⁴ Our Impact, Cancer Prevention & Research Institute of Texas website, <https://www.cprit.state.tx.us/our-programs/our-impact#>, accessed November 14, 2023; and CPRIT personnel.

California, the incremental economic benefits would include \$64.4 billion in gross product each year and about 354,306 jobs. The impacts from these scenarios are much larger than in previous years due to several factors including an additional three years of compounding to 2053 as well as Texas expecting to continue to experience higher growth in biosciences. CPRIT's continued successes as well as the recent announcement with Texas being one of three national hubs for ARPA-H will contribute to the higher growth.

It is worthy of note that, since 2010, Texas has seen growth in bioscience manufacturing employment of about 35.2%. The pace is far in excess of that of the United States (16.5%) and states that have traditionally been major centers of such activity. Expansion in competing states is far lower, including California (14.5%), North Carolina (14.4%), Illinois (13.8%), Georgia (10.6%), Massachusetts (5.9%), Ohio (4.7%), and Pennsylvania (-2.8%). While there are other factors that support the success in Texas. The investments and programs supported by CPRIT are the major differentiating factor.

A Broader Perspective

Scientific research, as is facilitated by CPRIT, is valuable to society in large part due to the benefits that it facilitates downstream and how it produces further research leading to additional advances.¹⁵ In traditional infrastructure such as

Scientific research, as is facilitated by CPRIT, is valuable to society in large part due to the benefits that it facilitates downstream.

roads, highways, water systems, and schools, the government typically plays a major role as provider, coordinator, or regulator.

Scientific research, specifically

cancer research, is much like traditional infrastructure because it creates benefits or value primarily from downstream uses and "contributes significantly to economic growth and social welfare."¹⁶

¹⁵ See for example, Frischman, Brett, "An Economic Theory of Infrastructure and Commons Management," American Law & Economics Association Annual Meetings, 2006.

¹⁶ Frischman, Brett, "An Economic Theory of Infrastructure and Commons Management," American Law & Economics Association Annual Meetings, 2006 p. 993.

Because of its inherent nature as infrastructure, cancer research and prevention should be funded and supported in a manner similar to that of traditional infrastructure. It is in essence a public good that benefits everyone in society although some of the specific benefits might not occur until well in the future.

Conclusion

The Cancer Prevention and Research Institute of Texas plays a crucial role in the war on cancer. Through its operations, screening/prevention efforts, and research programs, CPRIT is helping reduce the extremely high human and economic costs of cancer. CPRIT is also generating a sizable economic stimulus from all of its efforts including almost **\$23.8 billion** in output (gross product) and **201,911** jobs in 2023 (when multiplier and secondary effects are included). Moreover, the Institute's efforts to improve outcomes related to cancer prevention and treatment can lead to a significant reduction in cancer incidence and severity over time and be a catalyst to biomedical development in Texas.

CPRIT efforts improve outcomes related to cancer prevention and treatment, leading to a significant reduction in cancer incidence and severity over time. The Institute is also a catalyst to biomedical development in Texas.

The Institute's positive impact represents an excellent return on fiscal resources. Research enabled by grants funded through CPRIT is bearing fruit, with leading researchers as well as companies coming to the state, matching funds being attracted, and findings being published in leading journals. Empirical evidence shows that medical research and prevention programs can reduce cancer incidence and enhance outcomes. Reductions in treatment expenses, morbidity, and mortality stand to bring notable economic benefits.

Basic medical research is part of society's essential infrastructure, and CPRIT has demonstrated capacity to enhance the health of Texans and the economy at a pace that far exceeds the direct investment.

which exceed the investment of resources. The significance of CPRIT activities continues to expand and will only accelerate in the future now that its mission has been extended. **Basic medical research is a part of society's essential infrastructure, and CPRIT has demonstrated the capacity to enhance the health of Texans and the economy at a pace that far exceeds the direct investment.**